Takahashi Shin

タカハシシン | Takahashi Shin

Affiliation and department：
Job title： Graduate Student

Research field (5)： Tumor diagnostics and therapeutics , Tumor diagnostics and therapeutics , Tumor diagnostics and therapeutics , Gastroenterology , Medical biochemistry

Research keywords (4)： breast cancer , 消化器 , 癌 , cancer

Research theme for competitive and other funds (2)：

2001 - 癌の分子診断
2001 - Molecular diagnosis of cancer

Papers (31)：

Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H, et al. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. International journal of clinical oncology. 2018. 23. 4. 790-798
Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M, et al. Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey. Japanese journal of clinical oncology. 2018. 48. 10. 913-919
Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, et al. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. The Tohoku journal of experimental medicine. 2018. 245. 2. 123-129
Akira Okita, Shin Takahashi, Kota Ouchi, Masahiro Inoue, Mika Watanabe, Mareyuki Endo, Hiroshi Honda, Yasuhide Yamada, Chikashi Ishioka. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget. 2018. 9. 27. 18698-18711
Y. Yamada, T. Denda, M. Gamoh, I. Iwanaga, S. Yuki, H. Shimodaira, M. Nakamura, T. Yamaguchi, H. Ohori, K. Kobayashi, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): A randomized, open-label, phase III, noninferiority trial. Annals of Oncology. 2018. 29. 3. 624-631

ｍore...

Patents (3)：

遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法
大腸癌に対する薬物療法の感受性を予測する方法
がんの予後予測方法

Lectures and oral presentations (11)：

DNA メチル化状態は進行再発大腸癌に対する抗EGFR 抗体薬の治療効果予測性において原発巣の左右差より優れる
(第 16 回日本臨床腫瘍学会学術集会 2018)
早期乳がん予後予測バイオマーカーTP53 signature
(第26回日本乳癌学会学術総会 2018)
The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer
(2018 Gastrointestinal Cancers Symposium 2018)
Consensus Molecular Subtypes(CMS)は抗EGFR抗体薬の治療効果予測因子となる
(第76回日本癌学会学術総会 2017)
Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer
(ESMO2018 2017)

ｍore...

Education (1)：

1999 - 2005 東北大学大学院医学研究科

Professional career (1)：

医学博士 (東北大学大学院)

Awards (2)：

2015/04 - 日本内科学会奨励賞
2014/07 - 日本臨床腫瘍学会奨励賞

Association Membership(s) (5)：

日本治療学会 , 日本癌学会 , 内科学会 , Japanese Society of Clinical Oncology , Japanese Cancer Association

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page